These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 22938051)

  • 1. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Tarlatzi TB; Tarlatzis BC; Lainas TG
    Reprod Biol Endocrinol; 2012 Aug; 10():69. PubMed ID: 22938051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    Hum Reprod; 2013 Jul; 28(7):1929-42. PubMed ID: 23624582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy analysis of letrozole combined with gonadotropin-releasing hormone antagonists in patients with high risk of ovarian hyperstimulation syndrome undergoing total embryo freezing].
    Zhang YY; Zhang YL; Bu ZQ; Chen CH; Yang L; Meng YL; Guo YH
    Zhonghua Yi Xue Za Zhi; 2024 Aug; 104(30):2823-2829. PubMed ID: 39085150
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    BJOG; 2014 Jun; 121(7):848-55. PubMed ID: 24621101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist.
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Kolibianakis EM
    Reprod Biomed Online; 2007 Oct; 15(4):408-12. PubMed ID: 17908403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase.
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Alexopoulou E; Kolibianakis EM
    Reprod Biomed Online; 2009 Dec; 19(6):789-95. PubMed ID: 20031018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of severe OHSS using GnRH antagonist and blastocyst cryopreservation in PCOS patients treated with long protocol.
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Iliadis GS; Kolibianakis EM
    Reprod Biomed Online; 2009 Jan; 18(1):15-20. PubMed ID: 19146764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome.
    Lainas GT; Lainas TG; Venetis CA; Sfontouris IA; Zorzovilis IZ; Alexopoulou E; Tarlatzis BC; Kolibianakis EM
    Ultrasound Obstet Gynecol; 2018 Jan; 51(1):126-133. PubMed ID: 29105961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
    Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
    Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of luteal GnRH antagonist on moderate and severe early ovarian hyperstimulation syndrome during in vitro fertilization treatment: a prospective cohort study.
    Zeng C; Shang J; Jin AM; Wu PL; Li X; Xue Q
    Arch Gynecol Obstet; 2019 Jul; 300(1):223-233. PubMed ID: 31004220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
    Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
    Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
    Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GnRH antagonist administered twice the day before hCG trigger combined with a step-down protocol may prevent OHSS in IVF/ICSI antagonist cycles at risk for OHSS without affecting the reproductive outcomes: a prospective randomized control trial.
    Prapas Y; Ravanos K; Petousis S; Panagiotidis Y; Papatheodorou A; Margioula-Siarkou C; Iuliano A; Gullo G; Prapas N
    J Assist Reprod Genet; 2017 Nov; 34(11):1537-1545. PubMed ID: 28776117
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
    Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
    Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
    Griesinger G
    Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New algorithm for OHSS prevention.
    Papanikolaou EG; Humaidan P; Polyzos N; Kalantaridou S; Kol S; Benadiva C; Tournaye H; Tarlatzis B
    Reprod Biol Endocrinol; 2011 Nov; 9():147. PubMed ID: 22054506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Letrozole versus gonadotropin-releasing hormone antagonist during luteal phase in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial].
    Cheng ZX; Kong G; Zhang CL; Zhao YN
    Zhonghua Fu Chan Ke Za Zhi; 2020 Jan; 55(1):9-14. PubMed ID: 32074767
    [No Abstract]   [Full Text] [Related]  

  • 20. Combination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective study.
    Lin YH; Huang MZ; Hwang JL; Chen HJ; Hsieh BC; Huang LW; Tzeng CR; Seow KM
    J Assist Reprod Genet; 2013 Jun; 30(6):753-9. PubMed ID: 23606010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.